S. Hariharan

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

Stephen Leong, Roger B. Cohen, Daniel L. Gustafson et al. · Journal of Clinical Oncology · 2009 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17

Molecular analysis of astrocytomas presenting after age 10 in individuals with NF1

David H. Gutmann, C. David James, Minna Pöyhönen et al. · Neurology · 2003 · 84 citations

Medicine, Genetics, Molecular Genetics +17

Primary intracranial neoplasms in patients with HIV

Deborah T. Blumenthal, Jeffery J. Raizer, Marc K. Rosenblum et al. · Neurology · 1999 · 82 citations

Medicine, Infectious Diseases, Oncology +12

Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial.

Robert J. Motzer, Thomas E. Hutson, Mark R. Olsen et al. · Journal of Clinical Oncology · 2011 · 44 citations

Medicine, Oncology, Pharmacology +13

HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study

Laura Q.M. Chow, S. Gail Eckhardt, Daniel L. Gustafson et al. · Journal of Clinical Oncology · 2006 · 34 citations

Medicine, Oncology, Pharmacology +17